Dr Michelle Deaker

Managing Partner

BSc(Hons), MSc, PhD

 

 

 


ONEV-2657-BIOPROFILE2.jpg

Deal lead

Smart Sparrow | Incoming Media | Employment Hero | 8i

Location

Sydney

Founded

Networks beyond 2000 | E Com Industries  

Board roles

Seven West Media (ASX SWM) | Smart Sparrow | Incoming Media | Employment Hero | 8i | Head over Heels

Previous

NICTA (now Data 61) | AVCAL Venture Capital Working Group | NSW Government's Taskforce for the Digital Economy



Biography

Michelle is a Managing Partner of OneVentures and has been primarily responsible for the foundation of OneVentures firm and capital raisings of OneVentures Funds.  The firm now has $320M in funds under management. Michelle serves on the investment committee of OneVentures three main Funds, leads the technology practice within the firm and is responsible for investor relations managing the supervisory boards of OneVentures funds.

Michelle has over 20 years experience in the development of high growth technology companies in Australia and the US, has served on the boards of large and small listed and unlisted companies and has a strong background in Australian R&D and expertise in global business expansion. She has negotiated technology transfer contracts with research institutions; established financing syndicates with Australian, Asian and US investors; chaired the boards of several high growth companies; supported early breakthrough commercial contracts; leveraged her extensive networks for the benefit of OneVentures companies; and negotiated both financing and exit transactions.

Michelle established OneVentures in late 2006, coming into the venture capital industry as a successful IT industry business owner, entrepreneur and subsequently angel investor. The Company she founded in 1999, E Com Industries (www.giftvouchers.com), became the leading prepaid card and electronic voucher provider in Australia, servicing over 100 major retail brands including Coles Myer and Woolworths, managing $700m in Australian retail liability and eventually expanding operations into the United Kingdom, South Africa and New Zealand. E Com was acquired by UK publicly listed company, Retail Decisions, in 2005, in a transaction returning to investors 4.6xcapital and an average IRR of 70%. Notably, E Com industries was one of only a handful of Australian companies that successfully migrated the dotcom boom and crash through to a successful outcome for investors. Prior to E Com Industries, Michelle established IT enterprise business, Networks Beyond 2000.

Michelle holds a Bachelor of Science (Honours 1st class), Master of Science and a PhD (Applied Science).  She is a member of the Australian Institute of Company Directors and Chief Executive Women (CEW).


Dr Paul Kelly

Managing Partner

MBBS(Hons), MD, FRACP

 


ONEV-2869-BIOPROFILE.jpg

Deal lead

Hatchtech | Vaxxas | Clinical Genomics | Prota Therapeutics 

Location

Sydney

Founded/Co-founded

Gemini Genomics (Nasdaq:GMNI), merged with Sequenom (Nasdaq:SQNM) in 2001 | Atomera (Nasdaq:ATMR) | Agamatrix Inc.

Board roles

Vaxxas | Clinical Genomics | Find-Me Technologies | Hatchtech | Agamatrix Inc. | Garvan Institute of Medical Research

Previous

Charm Health | MedCenter Solutions | Orchid Cellmark | Gemini Genomics | American Society for Law, Medicine and Ethics



Biography

Paul has over 25 years experience in developing and commercialising biomedical innovations in United States, Europe, United Kingdom and Australia.   He has led early-stage and mid-stage companies achieve business results in order to attract funding and transform their ideas, technologies and products into sustainable successful businesses. Paul is currently Chair on the Boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of FindMe Technologies and Clinical Genomics. He is also non-executive director of US based Agamatrix Inc.

Paul joined the OneVentures team in 2009, prior to the launch of OneVenture’s first fund in 2010, after spending 15 years in the UK and USA (mostly in Boston, MA). Prior to joining OneVentures, Paul was CEO of Boston based Medcenter Holdings Inc. an on-line pharmaceutical marketing company, a position he held until December 2007. Previously he served as President and CEO of Orchid Cellmark (Nasdaq:ORCH), at that time the worlds leading provider of genetic testing services, from June 2003 until March 2006. During his tenure at both companies he developed and implemented major operational, financial and strategic restructuring. From 1995 to 2001, Paul served as CEO of Gemini Genomics (Nasdaq:GMNI), a clinical genomics company which he co-founded in 1995 to discover and commercialize novel gene-based targets. At Gemini, Paul positioned the company for one of the UK's largest biotechnology IPOs of the time, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the world's leading research institutions. In 2001, Paul oversaw the company's successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over $250M, after which he served for a short period as Executive Vice President.

Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specializing in endocrinology at St Vincent's Hospital, Sydney, Australia. While serving as a researcher at the Garvan Institute for Medical Research in Sydney, and in his postdoctoral work, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders, which have been published in leading journals such as Nature, New England Journal of Medicine, The Lancet, British Medical Journal and Proceedings of the National Academy of Science.

Paul has co-founded a number of other companies in the health sciences and technology arena, including Atomera Inc (Nasdaq: ATMR), based in Los Gatos, California and AgaMatrix, Inc (a consumer medical device company), based in New Hampshire, USA.

Paul has served on a number of national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. Paul is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Hons), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians. He also serves on the UNSW Medicine Dean's Advisory Group and serves on the Board of Directors of the Garvan Institute of Medical Research.


Anne-Marie Birkill

Managing Partner

BSc(Hons), MBA, FIML, GAICD

 


Michelle-Profile.png

Deal lead

Charm HealthFind-me Technologies | Peak3 | Paloma Mobile | Get Beasy (The Best Day)

Location

Brisbane

Board roles

Find-me Technologies (Chair) | Creative Enterprise Australia (Director) | Advance Queensland Business Development Fund (Member Investment Committee) | AVCAL (Council Member)

Previous

Charm Health | Peak3 | Paloma Mobile | Get Beasy | RedFlow | Springboard Enterprises

 

 



Biography

Anne-Marie is a Managing Partner, member of the Investment Committee, Executive Director of the Manager, Compliance Manager and Chair of the Risk Management Committee for OneVentures. She is based in Brisbane, a strong source of technology innovation opportunities.

She has over 25 years’ experience in commercialization and product development, during which time she has worked with hundreds of early stage technology companies and entrepreneurs as director, senior executive, mentor and business coach. Her interest in the technology sector was forged during 15 years in leadership roles in agri-business companies developing and commercialising new cultivars of ornamental, aquatic, food and forestry plants. She has successfully scaled businesses and has demonstrated a capacity to analyse and resolve operational problem areas. She has been a significant equity holder in both a plant breeding/propagation company and a boutique technology commercialisation firm. Prior to joining the OneVentures team in 2008, she was CEO of i.lab Incubator Pty Ltd, having previously spent five years in the senior management team at UniQuest. During this period Anne-Marie developed successful programs and networks to assist technology commercialization, start-up formation and growth, as well as capital raising and exit. She has experience of senior management in listed and unlisted companies and was a Director for energy storage company RedFlow Limited during its successful listing on the ASX (ASX:RFX).

Anne-Marie was Chair of the Board of Charm Health until September 2017 when she lead the company to an acquisition by the Citadel Group (ASX:CGL). She is currently Chair of the Board for OneVentures portfolio company Find-me technologies. Her experience and reputation in the technology sector is demonstrated through her active participation in the innovation community, including acting on national, state and university advisory Boards and Groups, and as judge for a number of technology awards programs. She is currently an Industry Fellow with The University of Queensland (UQ) Business School, a member of the AVCAL Council and a non-executive Director for Creative Enterprise Australia. She has also been invited speaker and presenter at a wide range of events, and is a mentor particularly for other women working in the technology industries. In 2013 she was honoured as one of YWCA Queensland’s 125 Leading Women. Her qualifications include a BSc(Hons) from Flinders University and an MBA from The University of Queensland, for which she was admitted to the Dean’s Honour Roll for Academic Excellence. She is a FAIM and a GAICD.

 


Dr Graeme Wald

Principal

B.Sc(Hons), PhD, MBA, GAICD

 


ONEV-2071-BIOPROFILE.jpg

Deal lead

Prota Therapeutics

Location

Melbourne

Founded

Gravitas Consulting & Investments Pty Ltd

Board roles

Prota Therapeutics (Chair)

Previous

Nexvet Biopharma | Saluda Pty Ltd. (alternate director)


Biography

Graeme has spent close to 25 years in financial markets as an equities analyst, fund manager and venture capitalist. He headed the Life Science research team at Wilson HTM and played a leading role in numerous IPOS’s and secondary raisings worth more than $750M.

Whilst at Wilson HTM, as head of Life Science Research, Graeme was rated top analyst in the pharmaceutical sector as measured by Starmine against recommendations and investor returns.

As non-executive director of Nexvet Biopharma he was chairman of the Audit and Risk committee and assisted in guiding the company to a NASDAQ listing.

Graeme is originally from South Africa. Whilst at Merill Lynch he was rated top analyst in the Pharmaceutical and Healthcare sector. He was also a member of the top rated Global Paper and Pulp Research team.

Graeme has a broad range of sector experience. He has covered sectors including Life Sciences, pharmaceuticals, health care, transport, and paper and pulp. He also has experience in setting general industrial investment strategies.

Graeme has worked in Israel, America and South Africa as a research chemist in the industrial and energy sectors.

He holds a PhD in chemistry and an MBA from the University of the Witwatersrand.


Dr Amir Zalcenstein

Investment Manager

PhD, MBA

 


ONEV-2568-BIOPROFILE.jpg


Biography

Amir Zalcenstein has relocated to Melbourne from Israel in 2014.  Prior to joining OneVentures and while in Israel, Amir was Head of Business Development for BiondVax, a publicly traded company developing a Universal Flu Vaccine. Prior, Amir served as CEO of Amorphical (developing the next generation of Calcium-based therapies) and SoluBest, a drug delivery company advancing a proprietary technology for oral delivery of insoluble drugs. 

Amir holds a PhD in Molecular Biology from the Weizmann Institute of Science and an Executive MBA from Technion, Israel. 

Amir brings a strong Israeli venture perspective to the team and extensive international operational experience.

Location

Melbourne

Founded

Targia Pharmaceuticals


Sarah Meibusch

Investment Manager

BAgrSc (Hons), M.P.S, GAICD

 


ONEV-2236-BIOPROFILE.jpg

Location

Brisbane


Biography

Sarah brings over 16 years of global life science business development and management experience, 11 of those years in the human healthcare industry, and the past 12 years working in the Brisbane biotechnology ecosystem. Her previous roles included 5 years scouting for Shire Pharmaceuticals, a global specialty pharmaceutical company (LON: SHP). Sarah sought technologies for Shire in Australia, New Zealand, Singapore, Taiwan, Korea and Japan including playing a key role in sourcing the $300M Fibrotech deal announced in 2015. Sarah has a strong operational understanding of the pharmaceutical and life science industries gained through senior management roles at the Progen Pharmaceuticals, The University of Queensland’s QAAFI institute, Beef CRC and Pyxis Genomics.

Sarah is a graduate of Cornell University (Masters of Professional Studies), University of Queensland (Bachelor of Agricultural Science, Biochemistry and Animal Science) and is a graduate of the Australian Institute of Company Directors (GAICD). She has also completed postgraduate courses at Harvard Business School focusing on negotiation and decision making.


Sakura Holloway

Investment Analyst

MSc, Patent Attorney


ONEV-2178-BIOPROFILE.jpg

Location

Sydney

 


Biography

Sakura brings a unique blend of skills that include a strong technical background in biological sciences, including immunology and molecular biology combined with intellectual property and commercial experience. Sakura has held business development and IP counsel positions in medical research institutes, and public and private biotechnology companies. Most recently Sakura was Chief IP counsel at Benitec Biopharma Ltd (Nasdaq: BNTC) where she was an integral team member in the Company’s US Nasdaq IPO. Prior to this position she held positions as head of commercialization for RNAi technology at CSIRO, and Business Development and IP manager at the Garvan Institute of Medical Research. Sakura also held the position of Director of IP at Cephalon Australia Pty Ltd (formerly Arana Therapeutics).

Sakura is a graduate of UTS with Bachelor of Science (Biomedical Science), Master of Science and Master of Intellectual property. She is also a registered patent attorney.

 


James McGrath

Investment Associate

 


ONEV-2025-BIOPROFILE.jpg

Location

Sydney

 


Biography

James joined OneVentures in 2015 as an Investment Analyst. 

James joined OneVentures from Allier Capital, a boutique investment bank focused on helping high growth TMT, consumer and health companies raise capital and achieve exits. Prior to this James worked in investment banking at Citi, Credit Suisse and Merrill Lynch and was a research intern at The Department of Foreign Affairs and Trade (China Economics Desk). 

His role encompasses opportunity identification, due diligence, negotiation, portfolio company support and exit strategy. 

James holds a Bachelor of Commerce and a Bachelor of Arts, with majors in Economics and Politics from the University Of Melbourne (Trinity College). 

James is a keen squash player and runner.

 


Helen Liu

Chief Financial Officer

CA

 


Michelle-Profile.png

Location

Sydney


Biography

Helen is responsible for OneVentures' accounting, fund administration and all compliance activities. Helen is also responsible for the financial and company secretarial affairs for 3 OneVentures investee companies. Helen has over 20 years of experience in accounting, finance, fund management and investment with 12 years spent in various executive roles with Allen & Buckeridge, an Australian venture capital firm.


Jelly Jakob

Accountant

FIPA


ONEV-2267-BIOPROFILE.jpg

Location

Sydney


Biography

Jelly is responsible for assisting in OneVentures' daily accounting, fund administration and compliance activities. Jelly has over 15 years of fund accounting experience having started her financial services career with Allen & Buckeridge in Sydney.


Walter Lewin

Chairman, Board of Directors

 

 


ONEV-2106-BIOPROFILE.jpg

Location

Sydney


Biography

Mr Lewin is Chair of the Board and Investment Committee for OneVentures Pty Ltd. He is a member of the Advisory Board of VGI Partners, a leading global investment firm based in Sydney and New York. He is a co-founder and Chairman of Our Energy Group, a clean energy company, and Indigenous Energy Group. Mr Lewin was a founding shareholding and Chair of the Advisory Board of OneVue (ASX: OVH) and was a founding shareholder and Executive Director of Reverse Corp (ASX: REF). Previously, he was a Managing Director of Ord Minnett and member of its Group Management Committee, a Principal of Elysium Capital Partners in London, a Managing Director (Equities) for Merrill Lynch in London after holding several positions in the Equities and Investment Banking divisions of SBC (now UBS) in London and SBC Dominguez Barry (now UBS) in Sydney.

Mr Lewin received a Bachelor of Commerce (First Class Honours) and a Bachelor of Laws (Honours) from University of Queensland. He was a visiting lecturer in business finance at the Queensland Institute of Technology. He received the Baillieu Research award in 1989.


Simon Moore

Directors

 


ONEV-2050-BIOPROFILE.jpg

Location

Sydney

 


Biography

Prior to founding Colinton Capital Partners, Simon was a Managing Director and Global Partner of the “The Carlyle Group”.

Prior to The Carlyle Group, Simon was a Managing Director and Investment Committee Member of Investcorp International, Inc. based in New York.  Prior to that, Simon worked in private equity investments and investment banking at J.P. Morgan & Co. in New York, Hong Kong and Melbourne.

Simon is currently a non-executive Director of Firstwave Cloud Technology Limited, a non -executive Director of TPI Enterprises, a non-executive Director of Mexican fast casual restaurant chain Guzman Y Gomez and a non-executive Director of venture capital Firm, One Ventures. 

Simon received honours degrees in law and commerce from University of Queensland.


Roger Massy-Greene

Director

 

 


ONEV-2012-BIOPROFILE.jpg

Location

Sydney

 


Biography

Roger is a director of OneVentures Pty Ltd, a technology venture capital firm, and is the principal shareholder and director of Eureka Capital Partners, a private investment concern. He is also a director of Illawarra Coke Company, an industrial land development concern. 

Mr Massy-Greene previously served as the Chair of Ausgrid, Endeavour Energy and Essential Energy, having been appointed by the NSW government in 2012 to oversee reform of the NSW electricity distribution sector.   

He previously co-founded the ASX 200 company Excel Coal Limited and its predecessor Resource Finance Corporation Ltd, and served as Chair of Excel Coal until its acquisition by Peabody Energy in 2006.   

Mr Massy-Greene serves as Chair of Eureka Benevolent Foundation, a family foundation focused on overcoming socio-economic disadvantage.  He is the President of Cranbrook School and a director of The Hunger Project in the USA and Australia.  


Connie Mckeage

Director

 

 


ONEV-2220-BIOPROFILE.jpg

Location

Sydney

 


Biography

Connie Mckeage has an enviable track record of leading teams that deliver. She sits on the OneVue Board and is Managing Director of the OneVue Group, an Australian All ordinaries listed company.  Connie joined the board of OneVentures, a leading Australian venture capital firm, as an independent Director in 2017.

Connie has extensive experience in the Australian, Asian, European and North American financial services markets which solidly underpins her role as Managing Director.

As acting CEO Connie drove the establishment of E*TRADE in Australia. She has also run a number of large scale projects as a senior executive of companies such as Bankers Trust Australia, Rothschild Australia Asset Management and Perpetual Funds Management where she held the role of Deputy Managing Director. Whilst Head of International based in the US for New River Technologies she was responsible for business growth focused on global IT, operational and business transformation.

Connie's expertise is taking businesses from start-up to grown up.

Connie was awarded the Centenary Medal for her contribution to Australian business leadership. She is a Founder of Financial Executive Women (FEW) and in 2015 was an Eastern Finalist for E&Y’s Entrepreneur of the Year. For two consecutive years she's also been a finalist for the prestigious ‘Woman of the Year' title at the Women in Financial Services Awards and was most recently recognised by Insights Success magazine as one of the “the 30 most influential Women in Business.”